Missense	O	O
mutations	O	O
in	O	O
the	O	O
most	O	O
ancient	O	O
residues	O	O
of	O	O
the	O	O
PAX6	O	O
paired	O	O
domain	O	O
underlie	O	O
a	O	O
spectrum	O	O
of	O	O
human	O	O
congenital	B-disease	B-disease
eye	I-disease	I-disease
malformations	I-disease	I-disease
.	O	O
TfR	O	O
HFE	O	O
stoichiometry	O	O
(	O	O
2	O	O
1	O	O
)	O	O
differs	O	O
from	O	O
TfR	O	O
transferrin	O	O
stoichiometry	O	O
(	O	O
2	O	O
2	O	O
)	O	O
,	O	O
implying	O	O
a	O	O
different	O	O
mode	O	O
of	O	O
binding	O	O
for	O	O
HFE	O	O
and	O	O
transferrin	O	O
to	O	O
TfR	O	O
,	O	O
consistent	O	O
with	O	O
our	O	O
demonstration	O	O
that	O	O
HFE	O	O
,	O	O
transferrin	O	O
,	O	O
and	O	O
TfR	O	O
form	O	O
a	O	O
ternary	O	O
complex	O	O
.	O	O
The	O	O
myotonic	B-disease	B-disease
dystrophy	I-disease	I-disease
(	O	O
DM	B-disease	O
)	O	O
mutation	O	O
is	O	O
an	O	O
unstable	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
,	O	O
present	O	O
at	O	O
a	O	O
copy	O	O
number	O	O
of	O	O
5	O	O
-	O	O
37	O	O
repeats	O	O
on	O	O
normal	O	O
chromosomes	O	O
but	O	O
amplified	O	O
to	O	O
50	O	O
-	O	O
3000	O	O
copies	O	O
on	O	O
DM	B-disease	B-disease
chromosomes	O	O
.	O	O
A	O	O
transcribed	O	O
sequence	O	O
identified	O	O
from	O	O
the	O	O
C04107	O	O
-	O	O
containing	O	O
BAC	O	O
was	O	O
found	O	O
to	O	O
be	O	O
homologous	O	O
to	O	O
a	O	O
gene	O	O
expressed	O	O
from	O	O
human	O	O
chromosome	O	O
2p13	O	O
-	O	O
p16	O	O
,	O	O
a	O	O
region	O	O
devoid	O	O
of	O	O
any	O	O
positional	O	B-disease
candidate	O	I-disease
genes	O	I-disease
.	O	O
Eight	O	O
of	O	O
the	O	O
cases	O	O
were	O	O
familial	O	B-disease
,	O	O
and	O	O
five	O	O
were	O	O
sporadic	O	B-disease
.	O	O
C5	O	O
was	O	O
undetectable	O	O
in	O	O
her	O	O
serum	O	O
by	O	O
both	O	O
immunodiffusion	O	O
and	O	O
hemolytic	O	B-disease
assays	O	I-disease
.	O	O
This	O	O
mutation	O	O
eliminates	O	O
the	O	O
ability	O	O
of	O	O
HFE	O	O
to	O	O
associate	O	O
with	O	O
beta2	O	O
-	O	O
microglobulin	O	O
(	O	O
beta2m	O	O
)	O	O
and	O	O
prevents	O	O
cell	O	O
-	O	O
surface	O	O
expression	O	O
.	O	O
We	O	O
proposed	O	O
and	O	O
tested	O	O
a	O	O
simple	O	O
model	O	O
for	O	O
correlation	O	O
between	O	O
genotype	O	B-disease
and	O	O
phenotypic	O	B-disease
outcome	O	I-disease
.	O	O
The	O	O
mutations	O	O
include	O	O
three	O	O
single	O	O
base	O	O
deletions	O	O
,	O	O
one	O	O
splice	O	O
site	O	O
mutation	O	O
and	O	O
10	O	O
missense	O	O
mutations	O	O
.	O	O
This	O	O
missense	O	O
mutation	O	O
,	O	O
which	O	O
replaces	O	O
Ala	O	O
with	O	O
Thr	O	O
,	O	O
is	O	O
frequent	O	O
among	O	O
FNDI	B-disease	B-disease
patients	O	O
and	O	O
is	O	O
thought	O	O
to	O	O
reduce	O	O
the	O	O
efficiency	O	O
of	O	O
cleavage	O	O
by	O	O
signal	O	O
peptidases	O	O
.	O	O
.	O	O
We	O	O
have	O	O
found	O	O
strong	O	O
evidence	O	O
for	O	O
a	O	O
locus	O	O
on	O	O
chromosome	O	O
4p	O	O
at	O	O
D4S2949	O	O
(	O	O
maximum	O	O
GENEHUNTER	O	O
-	O	O
PLUS	O	O
nonparametric	O	O
linkage	O	O
score	O	O
=	O	O
4	O	O
.	O	O
05	O	O
,	O	O
P	O	O
=	O	O
5	O	O
.	O	O
22	O	O
x	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
;	O	O
SIBPAL	O	O
Pempirical	O	O
value	O	O
<	O	O
3	O	O
x	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
)	O	O
and	O	O
suggestive	O	O
evidence	O	O
for	O	O
a	O	O
locus	O	O
on	O	O
chromosome	O	O
4q	O	O
at	O	O
D4S397	O	O
(	O	O
maximum	O	O
GENEHUNTER	O	O
-	O	O
PLUS	O	O
nonparametric	O	O
linkage	O	O
score	O	O
=	O	O
3	O	O
.	O	O
29	O	O
,	O	O
P	O	O
=	O	O
2	O	O
.	O	O
57	O	O
x	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
;	O	O
SIBPAL	O	O
Pempirical	O	O
value	O	O
<	O	O
1	O	O
x	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
)	O	O
that	O	O
are	O	O
linked	O	O
to	O	O
mental	O	B-disease
health	O	I-disease
wellness	O	I-disease
.	O	O
The	O	O
two	O	O
other	O	O
siblings	O	O
,	O	O
apparently	O	O
healthy	O	O
at	O	O
12	O	O
(	O	O
1	O	O
/	O	O
2	O	O
)	O	O
and	O	O
15	O	O
years	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
their	O	O
father	O	O
,	O	O
apparently	O	O
healthy	O	O
as	O	O
well	O	O
,	O	O
presented	O	O
ARSA	O	B-disease
and	O	O
GS	O	B-disease
values	O	O
within	O	O
the	O	O
range	O	O
of	O	O
MLD	B-disease	B-disease
patients	O	O
.	O	O
Allele	O	O
-	O	O
specific	O	O
PCR	O	O
indicated	O	O
that	O	O
the	O	O
probands	O	O
two	O	O
brothers	O	O
also	O	O
inherited	O	O
the	O	O
1195delC	O	B-disease
mutation	O	I-disease
from	O	O
their	O	O
heterozygous	O	O
mother	O	O
and	O	O
the	O	O
1936delG	O	B-disease
mutation	O	I-disease
from	O	O
their	O	O
homozygous	O	O
father	O	O
.	O	O
.	O	O
When	O	O
the	O	O
W474C	O	O
-	O	O
containing	O	O
alpha	O	O
-	O	O
subunit	O	O
was	O	O
transiently	O	O
co	O	O
-	O	O
expressed	O	O
with	O	O
the	O	O
beta	O	O
-	O	O
subunit	O	O
to	O	O
produce	O	O
Hex	O	O
A	O	O
(	O	O
alphabeta	O	O
)	O	O
in	O	O
COS	O	O
-	O	O
7	O	O
cells	O	O
,	O	O
the	O	O
mature	O	O
alpha	O	O
-	O	O
subunit	O	O
was	O	O
present	O	O
,	O	O
but	O	O
its	O	O
level	O	O
was	O	O
much	O	O
lower	O	O
than	O	O
that	O	O
from	O	O
normal	O	O
alpha	O	O
-	O	O
subunit	O	O
transfections	O	O
,	O	O
although	O	O
higher	O	O
than	O	O
in	O	O
those	O	O
cells	O	O
transfected	O	O
with	O	O
an	O	O
alpha	O	O
-	O	O
subunit	O	O
associated	O	O
with	O	O
infantile	O	B-disease
TSD	B-disease	I-disease
.	O	O
Identification	O	O
of	O	O
constitutional	O	O
WT1	O	O
mutations	O	O
,	O	O
in	O	O
patients	O	O
with	O	O
isolated	O	O
diffuse	B-disease	O
mesangial	I-disease	B-disease
sclerosis	I-disease	I-disease
,	O	O
and	O	O
analysis	O	O
of	O	O
genotype	O	O
/	O	O
phenotype	O	O
correlations	O	O
by	O	O
use	O	O
of	O	O
a	O	O
computerized	O	O
mutation	O	O
database	O	O
.	O	O
Oleic	O	O
and	O	O
erucic	O	O
acids	O	O
(	O	O
Lorenzos	O	B-disease
Oil	O	I-disease
)	O	O
were	O	O
administered	O	O
to	O	O
patients	O	O
1	O	O
and	O	O
4	O	O
,	O	O
but	O	O
sufficient	O	O
effectiveness	O	O
was	O	O
not	O	O
obtained	O	O
.	O	O
BACKGROUND	O	O
/	O	O
AIMS	O	O
The	O	O
development	O	O
of	O	O
colorectal	B-disease	B-disease
cancer	I-disease	I-disease
and	O	O
a	O	O
variable	O	O
range	O	O
of	O	O
extracolonic	O	O
manifestations	O	O
in	O	O
familial	B-disease	B-disease
adenomatous	I-disease	I-disease
polyposis	I-disease	I-disease
(	O	O
FAP	B-disease	O
)	O	O
is	O	O
the	O	O
result	O	O
of	O	O
the	O	O
dominant	O	O
inheritance	O	O
of	O	O
adenomatous	B-disease	B-disease
polyposis	I-disease	I-disease
coli	I-disease	I-disease
(	O	O
APC	B-disease	O
)	O	O
gene	O	O
mutations	O	O
.	O	O
These	O	O
results	O	O
indicate	O	O
the	O	O
usefulness	O	O
of	O	O
cycloheximide	O	O
treatment	O	O
in	O	O
evaluating	O	O
the	O	O
abnormal	O	O
processing	O	O
of	O	O
mRNA	O	O
due	O	O
to	O	O
splice	O	B-disease
-	O	I-disease
site	O	I-disease
mutations	O	I-disease
,	O	O
because	O	O
(	O	O
i	O	O
)	O	O
aberrant	O	O
splicing	O	O
often	O	O
generates	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
,	O	O
(	O	O
ii	O	O
)	O	O
transcripts	O	O
with	O	O
premature	O	O
termination	O	O
codons	O	O
can	O	O
occur	O	O
at	O	O
low	O	O
or	O	O
undetectable	O	O
levels	O	O
due	O	O
to	O	O
nonsense	O	B-disease
-	O	I-disease
mediated	O	I-disease
mRNA	O	I-disease
decay	O	I-disease
,	O	O
and	O	O
(	O	O
iii	O	O
)	O	O
the	O	O
levels	O	O
of	O	O
these	O	O
transcripts	O	O
can	O	O
be	O	O
increased	O	O
by	O	O
cycloheximide	O	O
.	O	O
Patient	O	O
2	O	O
was	O	O
homozygous	O	O
for	O	O
a	O	O
mutation	O	O
in	O	O
exon	O	O
2	O	O
(	O	O
C3804A	O	O
)	O	O
which	O	O
abolishes	O	O
POMC	O	B-disease
translation	O	I-disease
.	O	O
The	O	O
same	O	O
mutation	O	O
was	O	O
present	O	O
heterozygously	O	O
in	O	O
the	O	O
DNA	O	O
from	O	O
the	O	O
constitutional	O	O
cells	O	O
of	O	O
the	O	O
patient	O	O
,	O	O
proving	O	O
it	O	O
to	O	O
be	O	O
of	O	O
germline	O	B-disease
origin	O	I-disease
.	O	O
In	O	O
addition	O	O
,	O	O
PTEN	O	O
was	O	O
identified	O	O
as	O	O
the	O	O
susceptibility	O	O
gene	O	O
for	O	O
two	O	O
hamartoma	B-disease	O
syndromes	I-disease	O
Cowden	B-disease	B-disease
disease	I-disease	I-disease
(	O	O
CD	B-disease	O
;	O	O
MIM	O	O
158350	O	O
)	O	O
and	O	O
Bannayan	B-disease	B-disease
-	I-disease	I-disease
Zonana	I-disease	I-disease
(	I-disease	O
BZS	I-disease	O
)	I-disease	O
or	I-disease	O
Ruvalcaba	I-disease	B-disease
-	I-disease	I-disease
Riley	I-disease	I-disease
-	I-disease	I-disease
Smith	I-disease	I-disease
syndrome	I-disease	I-disease
(	O	O
MIM	O	O
153480	O	O
)	O	O
.	O	O
The	O	O
initial	O	O
mutation	O	O
was	O	O
shown	O	O
to	O	O
have	O	O
occurred	O	O
in	O	O
the	O	O
paternally	O	O
derived	O	O
RB1	O	B-disease
allele	O	I-disease
.	O	O
Factor	B-disease	B-disease
H	I-disease	I-disease
deficiency	I-disease	I-disease
is	O	O
the	O	O
only	O	O
complement	B-disease	O
deficiency	I-disease	O
associated	O	O
with	O	O
HUS	B-disease	B-disease
.	O	O
We	O	O
screened	O	O
80	O	O
prostate	B-disease	B-disease
tumors	I-disease	I-disease
by	O	O
microsatellite	O	O
analysis	O	O
and	O	O
found	O	O
chromosome	O	O
10q23	O	O
to	O	O
be	O	O
deleted	O	O
in	O	O
23	O	O
cases	O	O
.	O	O
Based	O	O
on	O	O
its	O	O
chromosomal	O	O
position	O	O
,	O	O
this	O	O
gene	O	O
is	O	O
a	O	O
candidate	O	O
for	O	O
conferring	O	O
susceptibility	O	O
to	O	O
diabetes	B-disease	B-disease
.	O	O
Once	O	O
the	O	O
diagnosis	O	O
is	O	O
suspected	O	O
,	O	O
physicians	O	O
must	O	O
use	O	O
serum	O	B-disease
ferritin	O	I-disease
levels	O	I-disease
and	O	O
hepatic	O	B-disease
iron	O	I-disease
stores	O	I-disease
on	O	O
liver	O	O
biopsy	O	O
specimens	O	O
to	O	O
assess	O	O
patients	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
iron	B-disease	B-disease
overload	I-disease	I-disease
.	O	O
Using	O	O
methylation	O	O
-	O	O
sensitive	O	O
restriction	O	O
enzymes	O	O
,	O	O
we	O	O
characterized	O	O
the	O	O
methylation	O	O
pattern	O	O
on	O	O
the	O	O
5	O	O
side	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
in	O	O
the	O	O
DMPK	O	O
gene	O	O
of	O	O
normal	O	O
individuals	O	O
and	O	O
of	O	O
patients	O	O
affected	O	O
with	O	O
myotonic	B-disease	B-disease
dystrophy	I-disease	I-disease
,	O	O
showing	O	O
expansions	O	O
of	O	O
the	O	O
repetitive	O	O
sequence	O	O
.	O	O
Maternal	B-disease	O
disomy	I-disease	O
and	O	O
Prader	B-disease	B-disease
-	I-disease	I-disease
Willi	I-disease	I-disease
syndrome	I-disease	I-disease
consistent	O	O
with	O	O
gamete	O	O
complementation	O	O
in	O	O
a	O	O
case	O	O
of	O	O
familial	O	O
translocation	O	O
(	O	O
3	O	O
;	O	O
15	O	O
)	O	O
(	O	O
p25	O	O
;	O	O
q11	O	O
.	O	O
2	O	O
)	O	O
.	O	O
In	O	O
patients	O	O
of	O	O
Dutch	O	O
ethnic	O	O
origin	O	O
,	O	O
however	O	O
,	O	O
no	O	O
significant	O	O
founder	O	B-disease
effect	O	I-disease
could	O	O
be	O	O
identified	O	O
.	O	O
RESULTS	O	O
In	O	O
persons	O	O
at	O	O
average	O	O
risk	O	O
for	O	O
colorectal	B-disease	B-disease
cancer	I-disease	I-disease
,	O	O
I1307K	O	O
was	O	O
found	O	O
in	O	O
5	O	O
.	O	O
It	O	O
is	O	O
believed	O	O
that	O	O
the	O	O
mutated	O	O
allele	O	O
of	O	O
PAX6	O	O
produces	O	O
an	O	O
inactive	O	O
protein	O	O
and	O	O
aniridia	B-disease	B-disease
is	O	O
caused	O	O
due	O	O
to	O	O
genetic	O	O
haploinsufficiency	O	B-disease
.	O	O
Previous	O	O
family	O	O
studies	O	O
suggested	O	O
that	O	O
these	O	O
individuals	O	O
may	O	O
be	O	O
compound	O	O
heterozygotes	O	O
for	O	O
the	O	O
common	O	O
mutant	O	O
TSD	B-disease	B-disease
gene	O	O
and	O	O
a	O	O
rare	O	O
(	O	O
allelic	O	O
)	O	O
mutant	O	O
gene	O	O
.	O	O
Very	O	O
nearly	O	O
all	O	O
mutations	O	B-disease
appear	O	O
to	O	O
cause	O	O
loss	O	O
of	O	O
function	O	O
of	O	O
the	O	O
mutant	O	O
allele	O	O
,	O	O
and	O	O
more	O	O
than	O	O
80	O	O
%	O	O
of	O	O
exonic	O	O
substitutions	O	O
result	O	O
in	O	O
nonsense	O	B-disease
codons	O	I-disease
.	O	O
The	O	O
first	O	O
predictive	O	O
testing	O	O
for	O	O
Huntington	B-disease	B-disease
disease	I-disease	I-disease
(	O	O
HD	B-disease	O
)	O	O
was	O	O
based	O	O
on	O	O
analysis	O	O
of	O	O
linked	O	O
polymorphic	O	O
DNA	O	O
markers	O	O
to	O	O
estimate	O	O
the	O	O
likelihood	O	O
of	O	O
inheriting	O	O
the	O	O
mutation	O	O
for	O	O
HD	B-disease	B-disease
.	O	O
Molecular	O	O
study	O	O
and	O	O
neuropsychological	O	O
analysis	O	O
were	O	O
performed	O	O
concurrently	O	O
on	O	O
49	O	O
patients	O	O
with	O	O
Duchenne	B-disease	B-disease
muscular	I-disease	I-disease
dystrophy	I-disease	I-disease
(	O	O
DMD	B-disease	O
)	O	O
in	O	O
order	O	O
to	O	O
find	O	O
a	O	O
molecular	O	O
explanation	O	O
for	O	O
the	O	O
cognitive	B-disease	O
impairment	I-disease	O
observed	O	O
in	O	O
most	O	O
DMD	B-disease	O
patients	O	O
.	O	O
Recent	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
hereditary	B-disease	B-disease
hemochromatosis	I-disease	I-disease
(	O	O
HH	B-disease	O
)	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
homozygosity	O	O
for	O	O
a	O	O
Cys282Tyr	O	O
mutation	O	O
in	O	O
the	O	O
HFE	O	O
gene	O	O
located	O	O
4	O	O
.	O	O
Strikingly	O	O
,	O	O
all	O	O
four	O	O
mutations	O	O
are	O	O
located	O	O
within	O	O
the	O	O
PAX6	O	B-disease
paired	O	O
domain	O	O
and	O	O
affect	O	O
amino	O	O
acids	O	O
which	O	O
are	O	O
highly	O	O
conserved	O	O
in	O	O
all	O	O
known	O	O
paired	O	O
domain	O	O
proteins	O	O
.	O	O
Thus	O	O
,	O	O
BRCA1	O	B-disease
and	O	O
BRCA2	O	B-disease
participate	O	O
,	O	O
together	O	O
,	O	O
in	O	O
a	O	O
pathway	O	O
(	O	O
s	O	O
)	O	O
associated	O	O
with	O	O
the	O	O
activation	O	O
of	O	O
double	O	O
-	O	O
strand	O	O
break	O	O
repair	O	O
and	O	O
/	O	O
or	O	O
homologous	O	O
recombination	O	O
.	O	O
The	O	O
smooth	O	O
pursuit	O	O
gain	O	O
was	O	O
decreased	O	O
.	O	O
Mutations	O	O
in	O	O
the	O	O
HEXA	O	O
gene	O	O
,	O	O
encoding	O	O
the	O	O
alpha	O	O
-	O	O
subunit	O	O
of	O	O
beta	O	O
-	O	O
hexosaminidase	O	O
A	O	O
(	O	O
Hex	O	O
A	O	O
)	O	O
,	O	O
that	O	O
abolish	O	O
Hex	O	O
A	O	O
enzyme	O	O
activity	O	O
cause	O	O
Tay	B-disease	B-disease
-	I-disease	I-disease
Sachs	I-disease	I-disease
disease	I-disease	I-disease
(	O	I-disease
TSD	B-disease	I-disease
)	O	I-disease
,	O	O
the	O	O
fatal	O	O
infantile	B-disease	O
form	I-disease	O
of	I-disease	O
G	I-disease	B-disease
(	I-disease	I-disease
M2	I-disease	I-disease
)	I-disease	I-disease
gangliosidosis	I-disease	I-disease
,	I-disease	I-disease
Type	I-disease	I-disease
1	I-disease	I-disease
.	O	O
Defective	O	O
thrombosis	B-disease	B-disease
in	O	O
mutant	O	O
mice	O	O
was	O	O
also	O	O
evident	O	O
in	O	O
an	O	O
in	O	O
vivo	O	O
model	O	O
of	O	O
vascular	B-disease	B-disease
injury	I-disease	I-disease
.	O	O
With	O	O
direct	O	O
tests	O	O
for	O	O
the	O	O
HD	B-disease	B-disease
mutation	O	I-disease
,	O	O
we	O	O
have	O	O
assessed	O	O
the	O	O
accuracy	O	O
of	O	O
results	O	O
obtained	O	O
by	O	O
linkage	O	O
approaches	O	O
when	O	O
requested	O	O
to	O	O
do	O	O
so	O	O
by	O	O
the	O	O
test	O	O
individuals	O	O
.	O	O
The	O	O
distribution	O	O
and	O	O
relative	O	O
frequencies	O	O
of	O	O
the	O	O
I113F	O	B-disease
and	O	O
T312S	O	B-disease
mutations	O	O
in	O	O
Australia	O	O
corresponded	O	O
to	O	O
those	O	O
observed	O	O
in	O	O
Northern	O	O
Ireland	O	O
and	O	O
are	O	O
unique	O	O
to	O	O
these	O	O
two	O	O
populations	O	O
,	O	O
suggesting	O	O
that	O	O
both	O	O
mutations	O	O
were	O	O
probably	O	O
introduced	O	O
to	O	O
Australia	O	O
by	O	O
Irish	O	O
migrants	O	O
during	O	O
the	O	O
19th	O	O
century	O	O
.	O	O
Germ	O	O
-	O	O
line	O	O
mutations	O	O
of	O	O
the	O	O
tumor	B-disease	O
suppressor	O	O
APC	O	O
are	O	O
implicated	O	O
in	O	O
attenuated	B-disease	B-disease
adenomatous	I-disease	I-disease
polyposis	I-disease	I-disease
coli	I-disease	I-disease
(	O	O
AAPC	B-disease	O
)	O	O
,	O	O
a	O	O
variant	O	O
of	O	O
familial	B-disease	B-disease
adenomatous	I-disease	I-disease
polyposis	I-disease	I-disease
(	O	O
FAP	B-disease	O
)	O	O
.	O	O
Overall	O	O
,	O	O
disease	O	B-disease
was	O	O
linked	O	O
to	O	O
BRCA1	O	O
in	O	O
an	O	O
estimated	O	O
52	O	O
%	O	O
of	O	O
families	O	O
,	O	O
to	O	O
BRCA2	O	O
in	O	O
32	O	O
%	O	O
of	O	O
families	O	O
,	O	O
and	O	O
to	O	O
neither	O	O
gene	O	O
in	O	O
16	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
6	O	O
%	O	O
-	O	O
28	O	O
%	O	O
)	O	O
,	O	O
suggesting	O	O
other	O	O
predisposition	O	O
genes	O	O
.	O	O
We	O	O
describe	O	O
the	O	O
outcome	O	O
of	O	O
a	O	O
5	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
with	O	O
VLCAD	B-disease	B-disease
deficiency	I-disease	I-disease
who	O	O
was	O	O
first	O	O
seen	O	O
at	O	O
5	O	O
months	O	O
of	O	O
age	O	O
with	O	O
severe	O	O
hypertrophic	B-disease	B-disease
cardiomyopathy	I-disease	I-disease
,	O	O
hepatomegaly	B-disease	B-disease
,	O	O
encephalopathy	B-disease	B-disease
,	O	O
and	O	O
hypotonia	B-disease	B-disease
.	O	O
Genomic	O	O
sequencing	O	O
of	O	O
a	O	O
BAC	O	O
clone	O	O
H	O	O
_	O	O
RG364P16	O	O
revealed	O	O
the	O	O
presence	O	O
of	O	O
another	O	O
,	O	O
highly	O	O
homologous	O	O
gene	O	O
3	O	O
of	O	O
the	O	O
CLD	B-disease	O
gene	O	O
,	O	O
with	O	O
a	O	O
similar	O	O
genomic	O	O
structure	O	O
,	O	O
recently	O	O
identified	O	O
as	O	O
the	O	O
Pendred	B-disease	B-disease
syndrome	I-disease	I-disease
gene	O	O
(	O	O
PDS	B-disease	O
)	O	O
.	O	O
.	O	O
This	O	O
is	O	O
corrected	O	O
by	O	O
the	O	O
reintroduction	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
VHL	B-disease	B-disease
,	O	O
implicating	O	O
VHL	B-disease	B-disease
as	O	O
the	O	O
first	O	O
tumor	B-disease	O
suppressor	O	O
involved	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
cell	O	O
cycle	O	O
exit	O	O
,	O	O
which	O	O
is	O	O
consistent	O	O
with	O	O
its	O	O
gatekeeper	O	O
function	O	O
in	O	O
the	O	O
kidney	O	O
.	O	O
.	O	O
The	O	O
hypothesis	O	O
that	O	O
SWS	B-disease	B-disease
and	O	O
SJS	B-disease	B-disease
type	I-disease	I-disease
2	I-disease	I-disease
are	O	O
the	O	O
same	O	O
disorder	O	O
should	O	O
be	O	O
testable	O	O
by	O	O
molecular	O	O
methods	O	O
.	O	O
.	O	O
Compared	O	O
with	O	O
the	O	O
frequency	O	O
in	O	O
two	O	O
separate	O	O
population	O	O
control	O	O
groups	O	O
,	O	O
the	O	O
APC	O	B-disease
I1307K	O	I-disease
allele	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
estimated	O	O
relative	O	O
risk	O	O
of	O	O
1	O	O
.	O	O
No	O	O
desmoid	B-disease	B-disease
tumors	I-disease	I-disease
were	O	O
found	O	O
in	O	O
these	O	O
kindreds	O	O
.	O	O
These	O	O
studies	O	O
suggest	O	O
that	O	O
the	O	O
genes	O	O
for	O	O
Factor	O	O
B	O	O
and	O	O
C2	B-disease	B-disease
deficiency	I-disease	I-disease
are	O	O
located	O	O
outside	O	O
those	O	O
for	O	O
HLA	O	O
,	O	O
that	O	O
the	O	O
order	O	O
of	O	O
genese	O	O
is	O	O
HLA	O	O
-	O	O
A	O	O
,	O	O
-	O	O
B	O	O
,	O	O
-	O	O
D	O	O
,	O	O
Factor	O	O
B	O	O
allotype	O	O
,	O	O
C2	B-disease	B-disease
deficiency	I-disease	I-disease
,	O	O
that	O	O
the	O	O
genes	O	O
coding	O	O
for	O	O
C2	B-disease	B-disease
deficiency	I-disease	I-disease
and	O	O
Factor	O	O
B	O	O
allotypes	O	O
are	O	O
approximately	O	O
3	O	O
-	O	O
-	O	O
5	O	O
centimorgans	O	O
from	O	O
the	O	O
HLA	O	O
-	O	O
A	O	O
and	O	O
HLA	O	O
-	O	O
B	O	O
loci	O	O
,	O	O
and	O	O
that	O	O
the	O	O
apparent	O	O
lack	O	O
of	O	O
recombinants	O	O
between	O	O
the	O	O
Factor	O	O
B	O	O
gene	O	O
and	O	O
C2	B-disease	B-disease
deficiency	I-disease	I-disease
gene	O	O
suggests	O	O
that	O	O
these	O	O
two	O	O
genes	O	O
lie	O	O
in	O	O
close	O	O
proximity	O	O
to	O	O
one	O	O
another	O	O
.	O	O
We	O	O
studied	O	O
somatic	O	O
instability	O	O
by	O	O
measuring	O	O
the	O	O
CTG	O	O
repeat	O	O
length	O	O
at	O	O
several	O	O
ages	O	O
in	O	O
various	O	O
tissues	O	O
of	O	O
transgenic	O	O
mice	O	O
carrying	O	O
a	O	O
(	O	O
CTG	O	O
)	O	O
55expansion	O	O
surrounded	O	O
by	O	O
45	O	O
kb	O	O
of	O	O
the	O	O
human	O	O
DM	B-disease	B-disease
region	O	O
,	O	O
using	O	O
small	O	O
-	O	O
pool	O	O
PCR	O	O
.	O	O
A	O	O
second	O	O
mutation	O	O
that	O	O
has	O	O
no	O	O
effect	O	O
on	O	O
beta2m	O	O
association	O	O
,	O	O
H63D	O	B-disease
,	O	O
was	O	O
found	O	O
in	O	O
eight	O	O
out	O	O
of	O	O
nine	O	O
patients	O	O
heterozygous	O	O
for	O	O
the	O	O
C282Y	O	B-disease
mutant	O	O
.	O	O
Cell	O	O
cycle	O	O
-	O	O
dependent	O	O
colocalization	O	O
of	O	O
BARD1	O	B-disease
and	O	O
BRCA1	O	B-disease
proteins	O	O
in	O	O
discrete	O	O
nuclear	O	O
domains	O	O
.	O	O
BACKGROUND	O	O
&	O	O
AIMS	O	O
Israeli	O	O
Jews	O	O
of	O	O
European	O	O
birth	O	O
,	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
Ashkenazim	O	O
,	O	O
have	O	O
the	O	O
highest	O	O
colorectal	B-disease	B-disease
cancer	I-disease	I-disease
incidence	O	O
of	O	O
any	O	O
Israeli	O	O
ethnic	O	O
group	O	O
.	O	O
To	O	O
test	O	O
for	O	O
possible	O	O
nosologic	O	O
identity	O	O
between	O	O
these	O	O
disorders	O	O
,	O	O
we	O	O
reviewed	O	O
the	O	O
literature	O	O
and	O	O
obtained	O	O
a	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
the	O	O
only	O	O
two	O	O
surviving	O	O
patients	O	O
,	O	O
one	O	O
with	O	O
SJS	B-disease	B-disease
type	I-disease	I-disease
2	I-disease	I-disease
at	O	O
age	O	O
10	O	O
years	O	O
and	O	O
another	O	O
with	O	O
SWS	B-disease	B-disease
at	O	O
age	O	O
7	O	O
years	O	O
.	O	O
To	O	O
obtain	O	O
clues	O	O
to	O	O
the	O	O
normal	O	O
biological	O	O
role	O	O
of	O	O
DMPK	O	O
in	O	O
cellular	O	O
ion	O	O
homeostasis	O	O
,	O	O
we	O	O
have	O	O
compared	O	O
the	O	O
resting	O	O
[	O	O
Ca2	O	O
+	O	O
]	O	O
i	O	O
,	O	O
the	O	O
amplitude	O	O
and	O	O
shape	O	O
of	O	O
depolarization	O	O
-	O	O
induced	O	O
Ca2	O	O
+	O	O
transients	O	O
,	O	O
and	O	O
the	O	O
content	O	O
of	O	O
ATP	O	O
-	O	O
driven	O	O
ion	O	O
pumps	O	O
in	O	O
cultured	O	O
skeletal	O	O
muscle	O	O
cells	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
and	O	O
DMPK	O	B-disease
[	O	I-disease
-	O	I-disease
/	O	I-disease
-	O	I-disease
]	O	I-disease
knockout	O	I-disease
mice	O	I-disease
.	O	O
Deletion	O	O
mapping	O	O
studies	O	O
have	O	O
unambiguously	O	O
identified	O	O
a	O	O
region	O	O
of	O	O
chromosome	O	O
10q23	O	O
to	O	O
be	O	O
the	O	O
minimal	O	O
area	O	O
of	O	O
loss	O	O
.	O	O
Six	O	O
of	O	O
eight	O	O
mutations	O	B-disease
were	O	O
observed	O	O
at	O	O
least	O	O
twice	O	O
.	O	O
The	O	O
disease	O	B-disease
susceptibility	O	I-disease
of	O	O
individuals	O	O
who	O	O
constitutionally	O	O
lack	O	O
both	O	O
wild	O	O
-	O	O
type	O	O
alleles	O	O
is	O	O
unknown	O	O
.	O	O
Identification	O	O
of	O	O
a	O	O
novel	O	O
nonsense	O	O
mutation	O	O
and	O	O
a	O	O
missense	O	O
substitution	O	O
in	O	O
the	O	O
vasopressin	O	O
-	O	O
neurophysin	O	O
II	O	O
gene	O	O
in	O	O
two	O	O
Spanish	O	O
kindreds	O	O
with	O	O
familial	B-disease	O
neurohypophyseal	I-disease	B-disease
diabetes	I-disease	I-disease
insipidus	I-disease	I-disease
.	O	O
To	O	O
date	O	O
,	O	O
mutation	O	O
screening	O	O
in	O	O
the	O	O
two	O	O
genes	O	O
has	O	O
been	O	O
hampered	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
genomic	O	O
structure	O	O
information	O	O
.	O	O
These	O	O
mutations	O	O
resulted	O	O
in	O	O
the	O	O
absence	O	O
or	O	O
a	O	O
dramatic	O	O
decrease	O	O
of	O	O
CPO	O	B-disease
activity	O	I-disease
.	O	O
These	O	O
findings	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
certain	O	O
alleles	O	O
could	O	O
prevent	O	O
or	O	O
modify	O	O
the	O	O
clinical	O	O
manifestations	O	O
of	O	O
BPAD	B-disease	B-disease
and	O	O
perhaps	O	O
other	O	O
related	O	O
affective	B-disease	B-disease
disorders	I-disease	I-disease
.	O	O
Reintroduced	O	O
wild	O	O
-	O	O
type	O	O
VHL	B-disease	O
strongly	O	O
inhibited	O	O
the	O	O
overexpression	O	O
of	O	O
the	O	O
CA12	O	O
gene	O	O
in	O	O
the	O	O
parental	O	O
renal	B-disease	B-disease
cell	I-disease	I-disease
carcinoma	I-disease	I-disease
cell	O	O
lines	O	O
.	O	O
A	O	O
variant	O	O
of	O	O
FAP	B-disease	B-disease
is	O	O
attenuated	B-disease	O
adenomatous	I-disease	B-disease
polyposis	I-disease	I-disease
coli	I-disease	I-disease
,	O	O
which	O	O
results	O	O
from	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
5	O	O
and	O	O
3	O	O
regions	O	O
of	O	O
the	O	O
APC	B-disease	B-disease
gene	O	I-disease
.	O	O
Ataxia	B-disease	B-disease
-	I-disease	I-disease
telangiectasia	I-disease	I-disease
(	O	I-disease
A	B-disease	I-disease
-	I-disease	I-disease
T	I-disease	I-disease
)	O	I-disease
is	O	O
a	O	O
recessive	B-disease	O
multi	I-disease	O
-	I-disease	O
system	I-disease	O
disorder	I-disease	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
at	O	O
11q22	O	O
-	O	O
q23	O	O
(	O	O
ref	O	O
.	O	O
3	O	O
)	O	O
.	O	O
Biochemical	O	O
studies	O	O
indicated	O	O
VLCAD	B-disease	B-disease
deficiency	I-disease	I-disease
caused	O	O
by	O	O
a	O	O
stable	O	O
yet	O	O
inactive	O	O
enzyme	O	O
.	O	O
To	O	O
date	O	O
,	O	O
several	O	O
mutations	O	O
in	O	O
the	O	O
Duchenne	B-disease	B-disease
muscular	I-disease	I-disease
dystrophy	I-disease	I-disease
gene	O	O
,	O	O
DMD	O	O
,	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
patients	O	O
with	O	O
XLDCM	B-disease	B-disease
,	O	O
but	O	O
a	O	O
pathogenic	O	O
correlation	O	O
of	O	O
these	O	O
cardiospecific	O	O
mutations	O	O
in	O	O
DMD	O	O
with	O	O
the	O	O
XLDCM	B-disease	B-disease
phenotype	O	O
has	O	O
remained	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O
Coincidence	O	O
of	O	O
two	O	O
novel	O	O
arylsulfatase	O	O
A	O	O
alleles	O	O
and	O	O
mutation	O	O
459	O	O
+	O	O
1G	O	O
>	O	O
A	O	O
within	O	O
a	O	O
family	O	O
with	O	O
metachromatic	B-disease	B-disease
leukodystrophy	I-disease	I-disease
:	O	O
molecular	O	O
basis	O	O
of	O	O
phenotypic	O	O
heterogeneity	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
a	O	O
correlation	O	O
between	O	O
smooth	O	O
pursuit	O	O
gain	O	O
and	O	O
the	O	O
number	O	O
of	O	O
trinucleotide	O	B-disease
repeats	O	I-disease
was	O	O
found	O	O
.	O	O
Of	O	O
51	O	O
ATM	O	O
mutations	O	O
identified	O	O
in	O	O
families	O	O
native	O	O
to	O	O
the	O	O
British	O	O
Isles	O	O
,	O	O
11	O	O
were	O	O
founder	O	O
mutations	O	O
,	O	O
and	O	O
2	O	O
of	O	O
these	O	O
11	O	O
conferred	O	O
a	O	O
milder	O	O
clinical	O	O
phenotype	O	O
with	O	O
respect	O	O
to	O	O
both	O	O
cerebellar	B-disease	B-disease
degeneration	I-disease	I-disease
and	O	O
cellular	O	O
features	O	O
.	O	O
We	O	O
examined	O	O
whether	O	O
the	O	O
WD	B-disease	B-disease
gene	O	O
ATP7B	O	O
was	O	O
also	O	O
causative	O	O
for	O	O
CT	B-disease	B-disease
by	O	O
investigating	O	O
the	O	O
chromosomal	O	O
co	O	O
-	O	O
localization	O	O
of	O	O
ATP7B	O	O
and	O	O
C04107	O	O
,	O	O
using	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
(	O	O
FISH	O	O
)	O	O
.	O	O
4	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
0	O	O
%	O	O
-	O	O
1	O	O
%	O	O
)	O	O
by	O	O
age	O	O
50	O	O
years	O	O
and	O	O
27	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
0	O	O
%	O	O
-	O	O
47	O	O
%	O	O
)	O	O
by	O	O
age	O	O
70	O	O
years	O	O
.	O	O
The	O	O
most	O	O
frequently	O	O
found	O	O
mutation	O	O
,	O	O
identified	O	O
in	O	O
three	O	O
unrelated	O	O
Turkish	O	O
A	B-disease	B-disease
-	I-disease	I-disease
T	I-disease	I-disease
individuals	O	O
,	O	O
was	O	O
previously	O	O
described	O	O
to	O	O
be	O	O
a	O	O
Turkish	O	O
A	B-disease	B-disease
-	I-disease	I-disease
T	I-disease	I-disease
founder	O	O
mutation	O	O
.	O	O
Germ	O	O
-	O	O
line	O	O
mutations	O	O
of	O	O
the	O	O
BRCA1	O	O
gene	O	O
predispose	O	O
women	O	O
to	O	O
early	O	O
-	O	O
onset	O	O
breast	B-disease	B-disease
and	I-disease	I-disease
ovarian	I-disease	I-disease
cancer	I-disease	I-disease
by	O	O
compromising	O	O
the	O	O
genes	O	O
presumptive	O	O
function	O	O
as	O	O
a	O	O
tumor	B-disease	O
suppressor	O	O
.	O	O
The	O	O
haplotyping	O	O
of	O	O
patients	O	O
with	O	O
identical	O	O
mutations	O	O
indicates	O	O
that	O	O
almost	O	O
all	O	O
of	O	O
these	O	O
represent	O	O
common	O	O
ancestry	O	O
and	O	O
that	O	O
very	O	O
few	O	O
spontaneously	O	O
recurring	O	O
ATM	O	B-disease
mutations	O	I-disease
exist	O	O
.	O	O
All	O	O
the	O	O
patients	O	O
carried	O	O
a	O	O
pathogenic	O	O
mutation	O	O
in	O	O
either	O	O
BRCA1	O	B-disease
(	O	O
179	O	O
women	O	O
)	O	O
or	O	O
BRCA2	O	B-disease
(	O	O
28	O	O
women	O	O
)	O	O
.	O	O
Recently	O	O
,	O	O
we	O	O
reported	O	O
five	O	O
Austrian	O	O
families	O	O
with	O	O
generalized	O	B-disease
atrophic	B-disease	I-disease
benign	I-disease	I-disease
epidermolysis	I-disease	I-disease
bullosa	I-disease	I-disease
who	O	O
share	O	O
the	O	O
same	O	O
COL17A1	O	B-disease
mutation	O	I-disease
.	O	O
The	O	O
other	O	O
allele	O	O
(	O	O
Hp2	O	O
)	O	O
of	O	O
individuals	O	O
with	O	O
Hp2	O	B-disease
/	O	I-disease
Hpdel	O	I-disease
was	O	O
found	O	O
to	O	O
have	O	O
,	O	O
in	O	O
all	O	O
exons	O	O
,	O	O
no	O	O
mutation	O	O
,	O	O
by	O	O
DNA	O	O
sequencing	O	O
.	O	O
It	O	O
is	O	O
crucial	O	O
to	O	O
diagnose	O	O
hemochromatosis	B-disease	B-disease
before	O	O
hepatic	B-disease	B-disease
cirrhosis	I-disease	I-disease
develops	O	O
because	O	O
phlebotomy	O	O
therapy	O	O
can	O	O
avert	O	O
serious	O	O
chronic	O	O
disease	O	O
and	O	O
can	O	O
even	O	O
lead	O	O
to	O	O
normal	O	O
life	O	O
expectancy	O	O
.	O	O
.	O	O
Low	O	O
levels	O	O
of	O	O
beta	O	B-disease
hexosaminidase	O	I-disease
A	O	I-disease
in	O	O
healthy	O	O
individuals	O	O
with	O	O
apparent	O	O
deficiency	O	O
of	O	O
this	O	O
enzyme	O	O
.	O	O
Human	O	O
MLH1	O	O
deficiency	O	O
predisposes	O	O
to	O	O
hematological	B-disease	B-disease
malignancy	I-disease	I-disease
and	O	O
neurofibromatosis	B-disease	B-disease
type	I-disease	I-disease
1	I-disease	I-disease
.	O	O
Uniparental	B-disease	O
disomy	I-disease	O
associated	O	O
with	O	O
unbalanced	O	O
segregation	O	O
of	O	O
non	O	O
-	O	O
Robertsonian	O	O
translocations	O	O
has	O	O
been	O	O
reported	O	O
previously	O	O
but	O	O
has	O	O
not	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
been	O	O
observed	O	O
in	O	O
a	O	O
case	O	O
of	O	O
PWS	B-disease	B-disease
.	O	O
In	O	O
males	O	O
,	O	O
SF	O	O
-	O	O
1	O	O
participates	O	O
in	O	O
sexual	O	O
development	O	O
by	O	O
regulating	O	O
expression	O	O
of	O	O
the	O	O
polypeptide	O	O
hormone	O	O
Mullerian	O	B-disease
inhibiting	O	I-disease
substance	O	I-disease
(	O	I-disease
MIS	O	I-disease
)	O	I-disease
.	O	O
Sporadic	B-disease	O
prostate	I-disease	B-disease
carcinoma	I-disease	I-disease
is	O	O
the	O	O
most	O	O
common	O	O
male	B-disease	O
cancer	I-disease	O
in	O	O
the	O	O
Western	O	O
world	O	O
,	O	O
yet	O	O
many	O	O
of	O	O
the	O	O
major	O	O
genetic	O	O
events	O	O
involved	O	O
in	O	O
the	O	O
progression	O	O
of	O	O
this	O	O
often	O	O
fatal	O	O
cancer	B-disease	O
remain	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O
Comparisons	O	O
with	O	O
allele	O	O
frequencies	O	O
based	O	O
on	O	O
prevalence	O	O
estimates	O	O
of	O	O
HH	B-disease	B-disease
showed	O	O
some	O	O
disagreements	O	O
with	O	O
the	O	O
RFLP	O	O
data	O	O
,	O	O
particularly	O	O
in	O	O
Finns	O	O
.	O	O
These	O	O
estimates	O	O
were	O	O
not	O	O
substantially	O	O
affected	O	O
either	O	O
by	O	O
changing	O	O
the	O	O
assumed	O	O
penetrance	O	O
model	O	O
for	O	O
BRCA1	O	B-disease
or	O	O
by	O	O
including	O	O
or	O	O
excluding	O	O
BRCA1	O	B-disease
mutation	O	O
data	O	O
.	O	O
Previous	O	O
studies	O	O
have	O	O
suggested	O	O
that	O	O
the	O	O
highly	O	O
variable	O	O
metabolic	O	O
phenotypes	O	O
of	O	O
PAH	B-disease	B-disease
deficiency	I-disease	I-disease
correlate	O	O
with	O	O
PAH	O	O
genotypes	O	O
.	O	O
In	O	O
total	O	O
,	O	O
one	O	O
or	O	O
both	O	O
of	O	O
these	O	O
mutations	O	B-disease
were	O	O
found	O	O
in	O	O
nine	O	O
of	O	O
the	O	O
14	O	O
families	O	O
analyzed	O	O
.	O	O
Three	O	O
novel	O	O
missense	O	O
mutations	O	O
never	O	O
identified	O	O
previously	O	O
in	O	O
other	O	O
populations	O	O
and	O	O
found	O	O
in	O	O
16	O	O
out	O	O
of	O	O
19	O	O
Colombian	O	O
MPS	B-disease	B-disease
IVA	I-disease	I-disease
unrelated	O	O
alleles	O	O
account	O	O
for	O	O
84	O	O
.	O	O
The	O	O
first	O	O
,	O	O
1195delC	O	O
located	O	O
in	O	O
exon	O	O
7	O	O
,	O	O
is	O	O
a	O	O
novel	O	O
mutation	O	O
,	O	O
while	O	O
the	O	O
second	O	O
,	O	O
1936delG	O	O
in	O	O
exon	O	O
12	O	O
,	O	O
has	O	O
been	O	O
described	O	O
before	O	O
to	O	O
cause	O	O
C6D	B-disease	B-disease
in	O	O
an	O	O
unrelated	O	O
African	O	O
-	O	O
American	O	O
individual	O	O
.	O	O
The	O	O
follow	O	O
-	O	O
up	O	O
observation	O	O
of	O	O
an	O	O
identical	O	O
and	O	O
unique	O	O
pattern	O	O
of	O	O
progressive	O	O
bone	B-disease	O
dysplasia	I-disease	O
in	O	O
the	O	O
two	O	O
patients	O	O
(	O	O
one	O	O
with	O	O
SJS	B-disease	B-disease
type	I-disease	I-disease
2	I-disease	I-disease
,	O	O
one	O	O
with	O	O
SWS	B-disease	B-disease
)	O	O
surviving	O	O
beyond	O	O
infancy	O	O
adds	O	O
to	O	O
the	O	O
evidence	O	O
in	O	O
favor	O	O
of	O	O
identity	O	O
.	O	O
However	O	O
,	O	O
genotype	O	O
-	O	O
phenotype	O	O
analysis	O	O
inthe	O	O
group	O	O
of	O	O
CD	B-disease	B-disease
families	O	O
revealed	O	O
two	O	O
possible	O	O
associations	O	O
worthy	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
in	O	O
independent	O	O
analyses	O	O
.	O	O
The	O	O
observed	O	O
genetic	O	O
heterogeneity	O	O
including	O	O
the	O	O
relative	O	O
high	O	O
percentage	O	O
of	O	O
splice	O	O
-	O	O
site	O	O
mutations	O	O
had	O	O
no	O	O
reflection	O	O
on	O	O
the	O	O
phenotype	O	B-disease
.	O	O
These	O	O
findings	O	O
show	O	O
that	O	O
BRCA1	O	O
is	O	O
implicated	O	O
in	O	O
a	O	O
small	O	O
fraction	O	O
of	O	O
breast	B-disease	B-disease
/	I-disease	I-disease
ovarian	I-disease	I-disease
cancer	I-disease	I-disease
families	O	O
suggesting	O	O
the	O	O
involvement	O	O
of	O	O
another	O	O
susceptibility	O	O
gene	O	O
(	O	O
s	O	O
)	O	O
This	O	O
disorder	O	O
is	O	O
reminiscent	O	O
of	O	O
another	O	O
rare	O	O
condition	O	O
,	O	O
the	O	O
Stuve	B-disease	B-disease
-	I-disease	I-disease
Wiedemann	I-disease	I-disease
syndrome	I-disease	I-disease
(	O	I-disease
SWS	B-disease	I-disease
)	O	I-disease
,	O	O
which	O	O
comprises	O	O
campomelia	B-disease	O
at	O	O
birth	O	O
with	O	O
skeletal	B-disease	B-disease
dysplasia	I-disease	I-disease
,	O	O
contractures	B-disease	B-disease
,	O	O
and	O	O
early	B-disease	O
death	I-disease	O
.	O	O
The	O	O
percentage	O	O
of	O	O
errors	O	O
in	O	O
antisaccades	O	O
was	O	O
greatly	O	O
increased	O	O
and	O	O
was	O	O
significantly	O	O
correlated	O	O
with	O	O
age	O	O
at	O	O
disease	O	B-disease
onset	O	I-disease
.	O	O
Colorectal	B-disease	B-disease
neoplasia	I-disease	I-disease
occurred	O	O
personally	O	O
or	O	O
in	O	O
the	O	O
families	O	O
of	O	O
13	O	O
of	O	O
20	O	O
Ashkenazi	O	O
I1307K	O	O
carriers	O	O
,	O	O
8	O	O
of	O	O
whom	O	O
also	O	O
had	O	O
a	O	O
personal	O	O
or	O	O
family	O	O
history	O	O
of	O	O
noncolonic	O	B-disease
neoplasia	B-disease	I-disease
.	O	O
B	O	O
.	O	O
We	O	O
propose	O	O
that	O	O
the	O	O
loss	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
VHL	B-disease	O
gene	O	O
results	O	O
in	O	O
a	O	O
specific	O	O
cellular	O	O
defect	O	O
in	O	O
serum	O	O
-	O	O
dependent	O	O
growth	O	O
control	O	O
,	O	O
which	O	O
may	O	O
initiate	O	O
tumor	B-disease	B-disease
formation	O	I-disease
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
direct	O	O
mutation	O	O
analysis	O	O
of	O	O
the	O	O
APC	B-disease	O
gene	O	O
was	O	O
performed	O	O
to	O	O
determine	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
for	O	O
nine	O	O
extracolonic	O	O
manifestations	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
incidence	O	O
of	O	O
APC	B-disease	B-disease
mutations	O	I-disease
in	O	O
non	O	O
-	O	O
FAP	O	B-disease
colorectal	B-disease	I-disease
cancer	I-disease	I-disease
.	O	O
However	O	O
,	O	O
several	O	O
truncation	O	O
mutations	O	O
have	O	O
been	O	O
found	O	O
to	O	O
occur	O	O
in	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
half	O	O
of	O	O
PAX6	O	O
in	O	O
patients	O	O
with	O	O
Aniridia	B-disease	B-disease
resulting	O	O
in	O	O
mutant	O	O
proteins	O	O
that	O	O
retain	O	O
the	O	O
DNA	O	O
-	O	O
binding	O	O
domains	O	O
but	O	O
have	O	O
lost	O	O
most	O	O
of	O	O
the	O	O
transactivation	O	O
domain	O	O
.	O	O
Among	O	O
these	O	O
mutations	O	O
two	O	O
are	O	O
missense	O	O
(	O	O
G197W	O	B-disease
,	O	O
W427R	O	B-disease
)	O	O
,	O	O
two	O	O
are	O	O
nonsense	O	O
(	O	O
Q306X	O	B-disease
,	O	O
Q385X	O	B-disease
)	O	O
,	O	O
two	O	O
are	O	O
small	O	O
deletions	O	O
(	O	O
662de14bp	O	B-disease
;	O	O
1168del3bp	O	B-disease
removing	O	O
a	O	O
glycine	O	O
at	O	O
position	O	O
390	O	O
)	O	O
,	O	O
and	O	O
one	O	O
is	O	O
a	O	O
splicing	O	O
mutation	O	O
(	O	O
IVS1	O	B-disease
-	O	I-disease
15c	O	I-disease
-	O	I-disease
-	O	I-disease
>	O	I-disease
g	O	I-disease
)	O	O
which	O	O
creates	O	O
a	O	O
new	O	O
acceptor	O	O
splice	O	O
site	O	O
.	O	O
Nonsense	O	O
mutation	O	O
in	O	O
exon	O	O
4	O	O
of	O	O
human	O	O
complement	O	O
C9	O	O
gene	O	O
is	O	O
the	O	O
major	O	O
cause	O	O
of	O	O
Japanese	O	O
complement	B-disease	B-disease
C9	I-disease	I-disease
deficiency	I-disease	I-disease
.	O	O
Germline	O	O
PTEN	O	B-disease
mutations	O	I-disease
were	O	O
identified	O	O
in	O	O
four	O	O
of	O	O
seven	O	O
(	O	O
57	O	O
%	O	O
)	O	O
BZS	B-disease	O
families	O	O
studied	O	O
.	O	O
This	O	O
should	O	O
help	O	O
in	O	O
the	O	O
design	O	O
of	O	O
tailored	O	O
clinical	O	O
-	O	O
management	O	O
protocols	O	O
in	O	O
this	O	O
subset	O	O
of	O	O
FAP	B-disease	B-disease
patients	O	O
.	O	O
.	O	O
The	O	O
fathers	O	O
genotype	O	O
thus	O	O
was	O	O
7delG	O	B-disease
/	O	O
A464V	O	B-disease
.	O	O
Here	O	O
,	O	O
it	O	O
is	O	O
shown	O	O
that	O	O
mouse	O	O
embryonic	O	O
stem	O	O
cells	O	O
deficient	B-disease	O
in	I-disease	O
BRCA1	I-disease	B-disease
are	O	O
defective	O	O
in	O	O
the	O	O
ability	O	O
to	O	O
carry	O	O
out	O	O
transcription	O	O
-	O	O
coupled	O	O
repair	O	O
of	O	O
oxidative	O	O
DNA	O	O
damage	O	O
,	O	O
and	O	O
are	O	O
hypersensitive	O	O
to	O	O
ionizing	O	O
radiation	O	O
and	O	O
hydrogen	O	B-disease
peroxide	O	I-disease
.	O	O
The	O	O
cornerstone	O	O
of	O	O
screening	O	O
and	O	O
case	O	O
detection	O	O
is	O	O
the	O	O
measurement	O	O
of	O	O
serum	O	O
transferrin	O	B-disease
saturation	O	I-disease
and	O	O
the	O	O
serum	O	O
ferritin	O	B-disease
level	O	I-disease
.	O	O
Immunohistochemical	O	O
staining	O	O
of	O	O
human	O	O
breast	O	O
specimens	O	O
also	O	O
revealed	O	O
BRCA1	O	O
nuclear	O	O
foci	O	O
in	O	O
benign	O	B-disease
breast	O	I-disease
,	O	O
invasive	B-disease	B-disease
lobular	I-disease	I-disease
cancers	I-disease	I-disease
and	O	O
low	B-disease	B-disease
-	I-disease	I-disease
grade	I-disease	I-disease
ductal	I-disease	I-disease
carcinomas	I-disease	I-disease
.	O	O
The	O	O
majority	O	O
(	O	O
81	O	O
%	O	O
)	O	O
of	O	O
the	O	O
breast	B-disease	B-disease
-	I-disease	I-disease
ovarian	I-disease	I-disease
cancer	I-disease	I-disease
families	O	O
were	O	O
due	O	O
to	O	O
BRCA1	O	O
,	O	O
with	O	O
most	O	O
others	O	O
(	O	O
14	O	O
%	O	O
)	O	O
due	O	O
to	O	O
BRCA2	O	O
.	O	O
A	O	O
Japanese	O	O
family	O	O
with	O	O
adrenoleukodystrophy	B-disease	B-disease
with	O	O
a	O	O
codon	O	O
291	O	O
deletion	O	O
:	O	O
a	O	O
clinical	O	O
,	O	O
biochemical	O	O
,	O	O
pathological	O	O
,	O	O
and	O	O
genetic	O	O
report	O	O
.	O	O
ATM	O	B-disease
mutations	O	I-disease
and	O	O
phenotypes	O	O
in	O	O
ataxia	B-disease	B-disease
-	I-disease	I-disease
telangiectasia	I-disease	I-disease
families	O	O
in	O	O
the	O	O
British	O	O
Isles	O	O
:	O	O
expression	O	O
of	O	O
mutant	O	O
ATM	O	O
and	O	O
the	O	O
risk	O	O
of	O	O
leukemia	B-disease	B-disease
,	O	O
lymphoma	B-disease	B-disease
,	O	O
and	O	O
breast	B-disease	B-disease
cancer	I-disease	I-disease
.	O	O
Genotype	O	O
-	O	O
phenotype	O	O
studies	O	O
were	O	O
not	O	O
performed	O	O
on	O	O
this	O	O
small	O	O
group	O	O
of	O	O
BZS	B-disease	B-disease
families	O	O
.	O	O
Both	O	O
A	B-disease	O
-	I-disease	O
T	I-disease	O
homozygotes	O	O
and	O	O
heterozygotes	O	O
showed	O	O
significantly	O	O
increased	O	O
levels	O	O
of	O	O
radiation	O	B-disease
-	O	I-disease
induced	O	I-disease
chromatid	O	I-disease
damage	O	I-disease
relative	O	O
to	O	O
that	O	O
of	O	O
normal	O	O
controls	O	O
.	O	O
Both	O	O
genomic	O	B-disease
mutations	O	I-disease
and	O	O
their	O	O
effects	O	O
on	O	O
cDNA	O	O
were	O	O
characterized	O	O
.	O	O
Ataxia	B-disease	B-disease
-	I-disease	I-disease
telangiectasia	I-disease	I-disease
:	O	O
identification	O	O
and	O	O
detection	O	O
of	O	O
founder	O	O
-	O	O
effect	O	O
mutations	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
in	O	O
ethnic	O	O
populations	O	O
.	O	O
In	O	O
1	O	O
patient	O	O
,	O	O
somatic	O	B-disease
mosaicism	O	I-disease
was	O	O
demonstrated	O	O
by	O	O
molecular	O	O
analysis	O	O
of	O	O
DNA	O	O
and	O	O
RNA	O	O
from	O	O
peripheral	O	O
blood	O	O
.	O	O
Molecular	O	O
genetic	O	O
analysis	O	O
of	O	O
her	O	O
VLCAD	O	B-disease
gene	O	O
revealed	O	O
a	O	O
T1372C	O	O
(	O	O
F458L	O	O
)	O	O
missense	O	O
mutation	O	O
and	O	O
a	O	O
1668	O	O
ACAG	O	O
1669	O	O
splice	O	O
site	O	O
mutation	O	O
.	O	O
We	O	O
also	O	O
show	O	O
that	O	O
in	O	O
all	O	O
informative	O	O
carrier	O	O
father	O	O
to	O	O
affected	O	O
child	O	O
transmissions	O	O
,	O	O
with	O	O
the	O	O
notable	O	O
exception	O	O
of	O	O
the	O	O
premutation	O	B-disease
carrier	O	I-disease
,	O	O
the	O	O
expansion	O	O
size	O	O
decreases	O	O
.	O	O
.	O	O
Emerin	O	O
is	O	O
a	O	O
nuclear	O	O
membrane	O	O
protein	O	O
which	O	O
is	O	O
missing	O	O
or	O	O
defective	O	O
in	O	O
Emery	B-disease	B-disease
-	I-disease	I-disease
Dreifuss	I-disease	I-disease
muscular	I-disease	I-disease
dystrophy	I-disease	I-disease
(	O	O
EDMD	B-disease	B-disease
)	O	O
.	O	O
Pulse	O	O
-	O	O
chase	O	O
analysis	O	O
using	O	O
proband	O	O
fibroblasts	O	O
revealed	O	O
that	O	O
the	O	O
W474C	O	O
-	O	O
containing	O	O
alpha	O	O
-	O	O
subunit	O	O
precursor	O	O
was	O	O
normally	O	O
synthesized	O	O
,	O	O
but	O	O
not	O	O
phosphorylated	O	O
or	O	O
secreted	O	O
,	O	O
and	O	O
the	O	O
mature	O	O
lysosomal	O	O
alpha	O	O
-	O	O
subunit	O	O
was	O	O
not	O	O
detected	O	O
.	O	O
However	O	O
,	O	O
immunostaining	O	O
revealed	O	O
that	O	O
BARD1	O	O
resides	O	O
within	O	O
BRCA1	O	O
nuclear	O	O
dots	O	O
during	O	O
S	O	O
phase	O	O
of	O	O
the	O	O
cell	O	O
cycle	O	O
,	O	O
but	O	O
not	O	O
during	O	O
the	O	O
G1	O	O
phase	O	O
.	O	O
This	O	O
mutation	O	O
may	O	O
be	O	O
valuable	O	O
for	O	O
developing	O	O
models	O	O
of	O	O
dominantly	B-disease	B-disease
inherited	I-disease	I-disease
neurodegeneration	I-disease	I-disease
,	O	O
as	O	O
the	O	O
early	O	O
age	O	O
of	O	O
onset	O	O
of	O	O
symptoms	O	O
suggests	O	O
that	O	O
this	O	O
mutation	O	O
may	O	O
be	O	O
particularly	O	O
deleterious	O	O
to	O	O
the	O	O
magnocellular	O	O
neuron	O	O
.	O	O
.	O	O
WFS1	O	O
appears	O	O
to	O	O
function	O	O
in	O	O
survival	O	O
of	O	O
islet	O	O
beta	O	O
-	O	O
cells	O	O
and	O	O
neurons	O	O
.	O	O
.	O	O
Further	O	O
evidence	O	O
for	O	O
a	O	O
major	O	O
ancient	O	O
mutation	O	O
underlying	O	O
myotonic	B-disease	B-disease
dystrophy	I-disease	I-disease
from	O	O
linkage	O	O
disequilibrium	O	O
studies	O	O
in	O	O
the	O	O
Japanese	O	O
population	O	O
.	O	O
Their	O	O
late	O	O
father	O	O
had	O	O
the	O	O
adult	O	O
type	O	O
of	O	O
DM	B-disease	B-disease
,	O	O
with	O	O
onset	O	O
around	O	O
30	O	O
years	O	O
.	O	O
However	O	O
,	O	O
direct	O	O
visualization	O	O
and	O	O
quantitation	O	O
of	O	O
hex	O	O
A	O	O
by	O	O
the	O	O
methods	O	O
described	O	O
may	O	O
prevent	O	O
false	O	O
-	O	O
positive	O	O
prenatal	O	O
diagnosis	O	O
of	O	O
TSD	B-disease	B-disease
in	O	O
fetuses	O	O
having	O	O
the	O	O
incomplete	O	O
hex	B-disease	O
A	I-disease	O
deficiency	I-disease	O
of	O	O
the	O	O
type	O	O
described	O	O
in	O	O
the	O	O
four	O	O
healthy	O	O
individuals	O	O
The	O	O
first	O	O
recognized	O	O
human	O	O
kindred	O	O
with	O	O
hereditary	B-disease	B-disease
deficiency	I-disease	I-disease
of	I-disease	O
the	I-disease	O
fifth	I-disease	O
component	I-disease	O
of	I-disease	O
complement	I-disease	O
(	O	O
C5	O	O
)	O	O
is	O	O
described	O	O
.	O	O
The	O	O
two	O	O
clinically	O	O
unaffected	O	B-disease
siblings	O	I-disease
carried	O	O
the	O	O
maternal	O	O
mutation	O	O
459	O	O
+	O	O
1G	O	O
>	O	O
A	O	O
and	O	O
,	O	O
on	O	O
their	O	O
paternal	O	O
allele	O	O
,	O	O
a	O	O
novel	O	O
cytosine	O	O
to	O	O
thymidine	O	O
transition	O	O
at	O	O
nucleotide	O	O
2435	O	O
in	O	O
exon	O	O
8	O	O
,	O	O
resulting	O	O
in	O	O
substitution	O	O
of	O	O
alanine	O	O
464	O	O
by	O	O
valine	O	O
(	O	O
A464V	O	O
)	O	O
.	O	O
Seventeen	O	O
mutations	O	O
were	O	O
distinct	O	O
,	O	O
of	O	O
which	O	O
10	O	O
were	O	O
not	O	O
reported	O	O
previously	O	O
.	O	O
Skin	O	B-disease
photosensitivity	O	I-disease
may	O	O
also	O	O
be	O	O
present	O	O
.	O	O
Like	O	O
BRCA1	O	B-disease
and	O	O
RAD51	O	B-disease
,	O	O
BRCA2	O	B-disease
relocates	O	O
to	O	O
PCNA	O	O
+	O	O
replication	O	O
sites	O	O
following	O	O
exposure	O	O
of	O	O
S	O	O
phase	O	O
cells	O	O
to	O	O
hydroxyurea	O	O
or	O	O
UV	O	O
irradiation	O	O
.	O	O
Since	O	O
a	O	O
mutation	O	O
at	O	O
cDNA	O	O
nucleotide	O	O
2302	O	O
(	O	O
2302insC	O	O
)	O	O
had	O	O
been	O	O
previously	O	O
described	O	O
,	O	O
this	O	O
region	O	O
of	O	O
the	O	O
ATP7B	O	O
gene	O	O
may	O	O
be	O	O
susceptible	O	O
to	O	O
gene	O	O
rearrangements	O	O
causing	O	O
Wilson	B-disease	B-disease
disease	I-disease	I-disease
.	O	O
In	O	O
an	O	O
attempt	O	O
to	O	O
resolve	O	O
this	O	O
issue	O	O
,	O	O
we	O	O
have	O	O
comprehensively	O	O
characterized	O	O
19	O	O
anti	O	O
-	O	O
BRCA1	O	B-disease
antibodies	O	O
.	O	O
The	O	O
somatic	O	O
mutation	O	O
rates	O	O
in	O	O
different	O	O
tissues	O	O
were	O	O
also	O	O
not	O	O
correlated	O	O
to	O	O
the	O	O
relative	O	O
inter	O	O
-	O	O
tissue	O	O
difference	O	O
in	O	O
transcriptional	O	O
levels	O	O
of	O	O
the	O	O
three	O	O
genes	O	O
(	O	O
DMAHP	O	B-disease
,	O	O
DMPK	O	B-disease
and	O	O
59	O	O
)	O	O
surrounding	O	O
the	O	O
repeat	O	O
.	O	O
.	O	O
We	O	O
have	O	O
also	O	O
mapped	O	O
two	O	O
highly	O	O
homologous	O	O
processed	O	O
pseudogenes	O	O
,	O	O
UBE3AP1	O	B-disease
and	O	O
UBE3AP2	O	B-disease
,	O	O
to	O	O
chromosomes	O	O
2	O	O
and	O	O
21	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
determined	O	O
their	O	O
genomic	O	O
organization	O	O
.	O	O
These	O	O
mice	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
reproduce	O	O
the	O	O
intergenerational	O	B-disease
and	O	O
somatic	O	B-disease
instability	O	I-disease
of	O	O
the	O	O
55	O	O
CTG	O	O
repeat	O	O
suggesting	O	O
that	O	O
surrounding	O	O
sequences	O	O
and	O	O
the	O	O
chromatin	O	O
environment	O	O
are	O	O
involved	O	O
in	O	O
instability	O	B-disease
mechanisms	O	I-disease
.	O	O
The	O	O
phenotypes	O	O
and	O	O
genotypes	O	O
in	O	O
one	O	O
of	O	O
these	O	O
three	O	O
families	O	O
showed	O	O
the	O	O
father	O	O
to	O	O
be	O	O
hypohaptoglobinemic	B-disease	B-disease
(	O	O
Hp2	O	O
)	O	O
and	O	O
Hp2	O	O
/	O	O
Hpdel	O	O
,	O	O
the	O	O
mother	O	O
to	O	O
be	O	O
Hp2	O	O
-	O	O
1	O	O
and	O	O
Hp1	O	O
/	O	O
Hp2	O	O
,	O	O
one	O	O
of	O	O
the	O	O
two	O	O
children	O	O
to	O	O
be	O	O
hypohaptoglobinemic	B-disease	B-disease
(	O	O
Hp2	O	O
)	O	O
and	O	O
Hp2	O	O
/	O	O
Hpdel	O	O
,	O	O
and	O	O
the	O	O
other	O	O
child	O	O
to	O	O
be	O	O
Hp1	O	O
and	O	O
Hp1	O	O
/	O	O
Hpdel	O	O
,	O	O
showing	O	O
an	O	O
anomalous	O	O
inheritance	O	O
of	O	O
Hp	O	O
phenotypes	O	O
in	O	O
the	O	O
child	O	O
with	O	O
Hp1	O	O
.	O	O
5	O	O
h	O	O
in	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
10	O	O
microg	O	O
cycloheximide	O	B-disease
per	O	O
ml	O	O
.	O	O
Studies	O	O
on	O	O
meiotic	O	O
drive	O	O
in	O	O
DM	B-disease	B-disease
have	O	O
shown	O	O
increased	O	O
transmission	O	O
of	O	O
the	O	O
larger	O	O
allele	O	O
at	O	O
the	O	O
DM	B-disease	B-disease
locus	O	O
in	O	O
non	O	O
-	O	O
DM	O	B-disease
heterozygotes	O	O
for	O	O
CTGn	O	O
.	O	O
We	O	O
studied	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
C9	B-disease	B-disease
deficiency	I-disease	I-disease
in	O	O
four	O	O
Japanese	O	O
C9	B-disease	B-disease
-	I-disease	I-disease
deficient	I-disease	I-disease
patients	O	O
who	O	O
had	O	O
suffered	O	O
from	O	O
meningococcal	B-disease	B-disease
meningitis	I-disease	I-disease
.	O	O
Among	O	O
the	O	O
other	O	O
11	O	O
unique	O	O
mutations	O	O
,	O	O
8	O	O
were	O	O
small	O	O
deletions	O	O
or	O	O
insertions	O	O
predicted	O	O
to	O	O
cause	O	O
frameshifts	O	B-disease
,	O	O
1	O	O
was	O	O
a	O	O
mutation	O	O
to	O	O
a	O	O
stop	O	O
codon	O	O
,	O	O
1	O	O
was	O	O
a	O	O
missense	O	B-disease
mutation	O	I-disease
,	O	O
and	O	O
1	O	O
was	O	O
predicted	O	O
to	O	O
cause	O	O
insertion	O	O
of	O	O
an	O	O
isoleucine	O	O
in	O	O
the	O	O
hect	O	O
domain	O	O
of	O	O
the	O	O
UBE3A	O	O
protein	O	O
,	O	O
which	O	O
functions	O	O
in	O	O
E2	O	O
binding	O	O
and	O	O
ubiquitin	O	B-disease
transfer	O	I-disease
.	O	O
Another	O	O
nephew	O	O
(	O	O
patient	O	O
4	O	O
)	O	O
of	O	O
patient	O	O
1	O	O
was	O	O
classified	O	O
as	O	O
having	O	O
an	O	O
adolescent	O	B-disease
form	O	I-disease
.	O	O
We	O	O
have	O	O
established	O	O
the	O	O
genomic	O	O
organization	O	O
of	O	O
UBE3A	O	O
and	O	O
the	O	O
sequence	O	O
of	O	O
intron	O	O
-	O	O
exon	O	O
borders	O	O
.	O	O
Additionally	O	O
,	O	O
the	O	O
X	O	O
-	O	O
linked	O	O
,	O	O
candidate	O	O
dosage	O	O
-	O	O
sensitive	O	O
sex	O	O
-	O	O
reversal	O	O
gene	O	O
,	O	O
Dax	O	B-disease
-	O	I-disease
1	O	I-disease
,	O	O
antagonizes	O	O
synergy	O	O
between	O	O
SF	O	O
-	O	O
1	O	O
and	O	O
WT1	O	B-disease
,	O	O
most	O	O
likely	O	O
through	O	O
a	O	O
direct	O	O
interaction	O	O
with	O	O
SF	O	O
-	O	O
1	O	O
.	O	O
X	B-disease	B-disease
-	I-disease	I-disease
linked	I-disease	I-disease
dilated	I-disease	I-disease
cardiomyopathy	I-disease	I-disease
(	O	I-disease
XLDCM	B-disease	I-disease
)	O	I-disease
is	O	O
a	O	O
clinical	O	O
phenotype	O	O
of	O	O
dystrophinopathy	B-disease	B-disease
which	O	O
is	O	O
characterized	O	O
by	O	O
preferential	O	O
myocardial	B-disease	O
involvement	I-disease	O
without	O	O
any	O	O
overt	O	O
clinical	O	O
signs	O	O
of	O	O
skeletal	B-disease	B-disease
myopathy	I-disease	I-disease
.	O	O
Recently	O	O
,	O	O
the	O	O
R496H	O	O
mutation	O	O
of	O	O
ARSA	O	O
was	O	O
proposed	O	O
to	O	O
be	O	O
a	O	O
cause	O	O
of	O	O
MLD	B-disease	B-disease
(	O	O
Draghia	O	O
et	O	O
al	O	O
.	O	O
,	O	O
1997	O	O
)	O	O
.	O	O
The	O	O
APCI1307K	O	O
allele	O	O
and	O	O
cancer	B-disease	B-disease
risk	O	O
in	O	O
a	O	O
community	O	O
-	O	O
based	O	O
study	O	O
of	O	O
Ashkenazi	O	O
Jews	O	O
.	O	O
Mutations	O	O
are	O	O
small	O	O
deletions	O	O
or	O	O
point	O	O
mutations	O	O
frequently	O	O
affecting	O	O
splice	O	O
sites	O	O
.	O	O
These	O	O
data	O	O
provide	O	O
further	O	O
evidence	O	O
for	O	O
extensive	O	O
allelic	O	O
heterogeneity	O	O
in	O	O
MPS	B-disease	B-disease
IVA	I-disease	I-disease
in	O	O
British	O	O
-	O	O
Irish	O	O
patients	O	O
and	O	O
provide	O	O
evidence	O	O
for	O	O
their	O	O
transmission	O	O
to	O	O
Australia	O	O
by	O	O
British	O	O
-	O	O
Irish	O	O
migrants	O	O
.	O	O
.	O	O
Autosomal	B-disease	B-disease
dominant	I-disease	I-disease
neurohypophyseal	I-disease	I-disease
diabetes	I-disease	I-disease
insipidus	I-disease	I-disease
associated	O	O
with	O	O
a	O	O
missense	O	O
mutation	O	O
encoding	O	O
Gly23	O	O
-	O	O
-	O	O
>	O	O
Val	O	O
in	O	O
neurophysin	O	O
II	O	O
.	O	O
The	O	O
corresponding	O	O
ovarian	B-disease	B-disease
cancer	I-disease	I-disease
risks	O	O
were	O	O
0	O	O
.	O	O
Liver	O	O
biopsy	O	O
is	O	O
also	O	O
used	O	O
to	O	O
establish	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
cirrhosis	B-disease	B-disease
,	O	O
which	O	O
can	O	O
affect	O	O
prognosis	O	O
and	O	O
management	O	O
.	O	O
Low	O	O
frequency	O	O
of	O	O
BRCA1	O	O
germline	O	O
mutations	O	O
in	O	O
45	O	O
German	O	O
breast	B-disease	B-disease
/	I-disease	I-disease
ovarian	I-disease	I-disease
cancer	I-disease	I-disease
families	O	O
.	O	O
One	O	O
missense	O	O
mutation	O	O
(	O	O
L236P	O	O
)	O	O
was	O	O
found	O	O
in	O	O
a	O	O
homozygous	O	O
state	O	O
in	O	O
two	O	O
consanguineous	O	O
families	O	O
and	O	O
in	O	O
a	O	O
heterozygous	O	O
state	O	O
in	O	O
five	O	O
additional	O	O
non	O	O
-	O	O
consanguineous	O	O
families	O	O
.	O	O
The	O	O
seven	O	O
exons	O	O
,	O	O
the	O	O
exon	O	O
/	O	O
intron	O	O
boundaries	O	O
and	O	O
part	O	O
of	O	O
3	O	O
noncoding	O	O
sequence	O	O
of	O	O
the	O	O
CPO	O	O
gene	O	O
were	O	O
systematically	O	O
analyzed	O	O
by	O	O
an	O	O
exon	O	O
-	O	O
by	O	O
-	O	O
exon	O	O
denaturing	O	O
gradient	O	O
gel	O	O
electrophoresis	O	O
(	O	O
DGGE	O	O
)	O	O
strategy	O	O
followed	O	O
by	O	O
direct	O	O
sequencing	O	O
in	O	O
seven	O	O
unrelated	O	O
heterozygous	O	O
HC	B-disease	B-disease
patients	O	O
from	O	O
France	O	O
,	O	O
Holland	O	O
,	O	O
and	O	O
Czech	O	O
Republic	O	O
.	O	O
Three	O	O
patients	O	O
with	O	O
the	O	O
I1307K	O	B-disease
allele	O	I-disease
were	O	O
detected	O	O
,	O	O
each	O	O
of	O	O
Ashkenazi	O	O
descent	O	O
.	O	O
Three	O	O
major	O	O
criteria	O	O
,	O	O
saccade	O	O
amplitude	O	O
,	O	O
saccade	O	O
velocity	O	O
,	O	O
and	O	O
presence	O	O
of	O	O
gaze	B-disease	O
-	I-disease	O
evoked	I-disease	O
nystagmus	I-disease	O
,	O	O
permitted	O	O
the	O	O
correct	O	O
assignment	O	O
of	O	O
90	O	O
%	O	O
of	O	O
the	O	O
SCA1	B-disease	B-disease
,	O	O
90	O	O
%	O	O
of	O	O
the	O	O
SCA2	B-disease	B-disease
,	O	O
and	O	O
93	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
SCA3	B-disease	B-disease
to	O	O
their	O	O
genetically	O	O
confirmed	O	O
patient	O	O
group	O	O
and	O	O
,	O	O
therefore	O	O
,	O	O
may	O	O
help	O	O
orient	O	O
diagnoses	O	O
of	O	O
SCA1	B-disease	B-disease
,	O	O
SCA2	B-disease	B-disease
,	O	O
and	O	O
SCA3	B-disease	B-disease
at	O	O
early	O	O
clinical	O	O
stages	O	O
of	O	O
the	O	O
diseases	O	O
.	O	O
.	O	O
Protein	O	O
-	O	O
truncation	O	O
testing	O	O
of	O	O
the	O	O
entire	O	O
ATM	O	O
cDNA	O	O
detected	O	O
92	O	O
(	O	O
66	O	O
%	O	O
)	O	O
truncating	O	O
mutations	O	O
in	O	O
140	O	O
mutant	O	O
alleles	O	O
screened	O	O
.	O	O
We	O	O
report	O	O
the	O	O
spectrum	O	O
of	O	O
59	O	O
ATM	O	O
mutations	O	O
observed	O	O
in	O	O
ataxia	B-disease	B-disease
-	I-disease	I-disease
telangiectasia	I-disease	I-disease
(	O	O
A	B-disease	O
-	I-disease	O
T	I-disease	O
)	O	O
patients	O	O
in	O	O
the	O	O
British	O	O
Isles	O	O
.	O	O
The	O	O
mutant	O	O
myotubes	O	B-disease
exhibit	O	O
smaller	O	O
and	O	O
slower	O	O
Ca2	O	O
+	O	O
responses	O	O
upon	O	O
triggering	O	O
by	O	O
acetylcholine	O	O
or	O	O
high	O	O
external	O	O
K	O	O
+	O	O
.	O	O
Qualitative	O	O
analysis	O	O
of	O	O
the	O	O
Dp71	O	B-disease
transcript	O	O
and	O	O
testing	O	O
for	O	O
the	O	O
specific	O	O
first	O	O
exon	O	O
of	O	O
Dp140	O	B-disease
were	O	O
also	O	O
carried	O	O
out	O	O
.	O	O
Previous	O	O
UBE3A	O	B-disease
cDNA	O	I-disease
analysis	O	O
has	O	O
shown	O	O
a	O	O
coding	O	O
region	O	O
of	O	O
approximately	O	O
2	O	O
.	O	O
In	O	O
this	O	O
study	O	O
we	O	O
investigated	O	O
45	O	O
German	O	O
breast	B-disease	B-disease
/	I-disease	I-disease
ovarian	I-disease	I-disease
cancer	I-disease	I-disease
families	O	O
for	O	O
germline	O	O
mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
.	O	O
12	O	O
families	O	O
with	O	O
15	O	O
matings	O	O
informative	O	O
for	O	O
C2	B-disease	B-disease
deficiency	I-disease	I-disease
were	O	O
found	O	O
.	O	O
Patients	O	O
with	O	O
generalized	O	B-disease
atrophic	B-disease	I-disease
benign	I-disease	I-disease
epidermolysis	I-disease	I-disease
bullosa	I-disease	I-disease
,	O	O
a	O	O
usually	O	O
nonlethal	O	O
form	O	O
of	O	O
junctional	B-disease	B-disease
epidermolysis	I-disease	I-disease
bullosa	I-disease	I-disease
,	O	O
have	O	O
generalized	O	O
blistering	B-disease	O
,	O	O
nail	B-disease	B-disease
dystrophy	I-disease	I-disease
,	O	O
patchy	B-disease	B-disease
alopecia	I-disease	I-disease
,	O	O
and	O	O
dental	B-disease	B-disease
abnormalities	I-disease	I-disease
.	O	O
We	O	O
extended	O	O
our	O	O
analysis	O	O
to	O	O
other	O	O
non	O	O
-	O	O
Ashkenazi	O	O
subsets	O	O
354	O	O
of	O	O
Moroccan	O	O
origin	O	O
,	O	O
200	O	O
Yemenites	O	O
and	O	O
150	O	O
Iranian	O	O
Jews	O	O
.	O	O
Although	O	O
increasing	O	O
measured	O	O
allele	O	O
size	O	O
between	O	O
patients	O	O
clearly	O	O
correlates	O	O
with	O	O
an	O	O
increased	O	O
severity	O	O
of	O	O
symptoms	O	B-disease
and	O	O
an	O	O
earlier	O	O
age	O	O
of	O	O
onset	O	B-disease
,	O	O
this	O	O
correlation	O	O
is	O	O
not	O	O
precise	O	O
and	O	O
measured	O	O
allele	O	O
length	O	O
cannot	O	O
be	O	O
used	O	O
as	O	O
an	O	O
accurate	O	O
predictor	O	O
of	O	O
age	O	O
of	O	O
onset	O	B-disease
.	O	O
Seven	O	O
novel	O	O
mutations	O	O
and	O	O
two	O	O
new	O	O
polymorphisms	O	O
were	O	O
detected	O	O
.	O	O
Although	O	O
hemochromatosis	B-disease	B-disease
is	O	O
common	O	O
in	O	O
Caucasians	O	O
,	O	O
affecting	O	O
>	O	O
=	O	O
1	O	O
/	O	O
300	O	O
individuals	O	O
of	O	O
northern	O	O
European	O	O
origin	O	O
,	O	O
it	O	O
has	O	O
not	O	O
been	O	O
recognized	O	O
in	O	O
other	O	O
populations	O	O
.	O	O
A	O	O
crossover	O	O
was	O	O
shown	O	O
to	O	O
have	O	O
occurred	O	O
between	O	O
genes	O	O
for	O	O
Factor	O	B-disease
B	O	I-disease
and	O	O
HLA	O	B-disease
-	O	I-disease
D	O	I-disease
,	O	O
in	O	O
which	O	O
HLA	O	B-disease
-	O	I-disease
D	O	I-disease
segregared	O	O
with	O	O
HLA	O	B-disease
-	O	I-disease
A	O	I-disease
and	O	O
B	O	B-disease
.	O	O
In	O	O
EDMD	B-disease	B-disease
,	O	O
the	O	O
additional	O	O
absence	O	O
of	O	O
lamin	O	O
B1	O	O
from	O	O
heart	O	O
and	O	O
skeletal	O	O
muscle	O	O
nuclei	O	O
which	O	O
already	O	O
lack	O	O
emerin	O	O
may	O	O
offer	O	O
an	O	O
alternative	O	O
explanation	O	O
of	O	O
why	O	O
these	O	O
tissues	O	O
are	O	O
particularly	O	O
affected	O	O
.	O	O
.	O	O
9	O	O
%	O	O
of	O	O
total	O	O
beta	O	O
hexosaminidase	O	O
activity	O	O
,	O	O
has	O	O
been	O	O
obtained	O	O
by	O	O
cellulose	O	O
acetate	O	O
gel	O	O
electrophoresis	O	O
,	O	O
DEAE	O	O
-	O	O
cellulose	O	O
ion	O	O
-	O	O
exchange	O	O
chromatography	O	O
,	O	O
radial	O	O
immunodiffusion	O	O
,	O	O
and	O	O
radioimmunoassay	O	O
.	O	O
Both	O	O
the	O	O
protein	O	O
truncation	O	O
test	O	O
(	O	O
PTT	O	O
)	O	O
and	O	O
the	O	O
restriction	O	O
endonuclease	O	O
fingerprinting	O	O
(	O	O
REF	O	O
)	O	O
method	O	O
were	O	O
used	O	O
and	O	O
compared	O	O
for	O	O
their	O	O
detection	O	O
efficiency	O	O
,	O	O
identifying	O	O
76	O	O
%	O	O
and	O	O
60	O	O
%	O	O
of	O	O
the	O	O
mutations	O	O
,	O	O
respectively	O	O
.	O	O
A	O	O
deletion	O	O
mutation	O	O
in	O	O
COL17A1	O	O
in	O	O
five	O	O
Austrian	O	O
families	O	O
with	O	O
generalized	O	B-disease
atrophic	B-disease	I-disease
benign	I-disease	I-disease
epidermolysis	I-disease	I-disease
bullosa	I-disease	I-disease
represents	O	O
propagation	O	O
of	O	O
an	O	O
ancestral	O	O
allele	O	O
.	O	O
Normal	O	O
hemolytic	O	O
titers	O	O
were	O	O
restored	O	O
to	O	O
both	O	O
homozygous	O	O
C5	B-disease	B-disease
-	I-disease	I-disease
deficient	I-disease	I-disease
(	O	I-disease
C5D	B-disease	I-disease
)	O	I-disease
sera	O	O
by	O	O
addition	O	O
of	O	O
highly	O	O
purified	O	O
human	O	O
C5	O	O
.	O	O
Oral	O	O
-	O	O
contraceptive	O	O
use	O	O
protected	O	O
against	O	O
ovarian	B-disease	B-disease
cancer	I-disease	I-disease
both	O	O
for	O	O
carriers	O	O
of	O	O
the	O	O
BRCA1	O	O
mutation	O	O
(	O	O
odds	O	O
ratio	O	O
,	O	O
0	O	O
.	O	O
5	O	O
;	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O
3	O	O
to	O	O
0	O	O
.	O	O
9	O	O
)	O	O
and	O	O
for	O	O
carriers	O	O
of	O	O
the	O	O
BRCA2	O	O
mutation	O	O
(	O	O
odds	O	O
ratio	O	O
,	O	O
0	O	O
.	O	O
4	O	O
;	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O
2	O	O
to	O	O
1	O	O
.	O	O
1	O	O
)	O	O
.	O	O
Congenital	B-disease	B-disease
chloride	I-disease	I-disease
diarrhea	I-disease	I-disease
(	O	O
CLD	B-disease	O
)	O	O
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
a	O	O
gene	O	O
which	O	O
encodes	O	O
an	O	O
intestinal	O	O
anion	O	O
transporter	O	O
.	O	O
We	O	O
report	O	O
on	O	O
an	O	O
unusual	O	O
case	O	O
of	O	O
maternal	B-disease	O
disomy	I-disease	O
15	I-disease	O
in	O	O
PWS	B-disease	B-disease
that	O	O
is	O	O
most	O	O
consistent	O	O
with	O	O
adjacent	O	O
-	O	O
1	O	O
segregation	O	O
of	O	O
a	O	O
paternal	O	O
t	O	O
(	O	O
3	O	O
;	O	O
15	O	O
)	O	O
(	O	O
p25	O	O
;	O	O
q11	O	O
.	O	O
2	O	O
)	O	O
with	O	O
simultaneous	O	O
maternal	O	O
meiotic	O	O
nondisjunction	O	O
for	O	O
chromosome	O	O
15	O	O
.	O	O
2	O	O
-	O	O
22	O	O
.	O	O
Stable	O	O
interaction	O	O
between	O	O
the	O	O
products	O	O
of	O	O
the	O	O
BRCA1	O	B-disease
and	O	O
BRCA2	O	B-disease
tumor	B-disease	O
suppressor	O	O
genes	O	O
in	O	O
mitotic	O	O
and	O	O
meiotic	O	O
cells	O	O
.	O	O
By	O	O
investigating	O	O
the	O	O
common	O	O
autosomal	O	O
recessive	O	O
copper	B-disease	B-disease
toxicosis	I-disease	I-disease
(	O	O
CT	B-disease	O
)	O	O
in	O	O
Bedlington	O	O
terriers	O	O
,	O	O
we	O	O
have	O	O
identified	O	O
a	O	O
new	O	O
locus	O	O
involved	O	O
in	O	O
progressive	O	B-disease
liver	B-disease	I-disease
disease	I-disease	I-disease
.	O	O
Mutations	O	O
were	O	O
detected	O	O
in	O	O
21	O	O
(	O	O
91	O	O
%	O	O
)	O	O
of	O	O
23	O	O
tumors	B-disease	O
with	O	O
LOH	O	B-disease
.	O	O
The	O	O
pathological	O	O
significance	O	O
of	O	O
the	O	O
point	O	O
mutations	O	O
G197W	O	B-disease
,	O	O
W427R	O	B-disease
,	O	O
and	O	O
the	O	O
in	O	O
-	O	O
frame	O	O
deletion	O	O
390delGly	O	B-disease
were	O	O
assessed	O	O
by	O	O
their	O	O
respective	O	O
expression	O	O
in	O	O
a	O	O
prokaryotic	O	O
system	O	O
using	O	O
site	O	O
-	O	O
directed	O	O
mutagenesis	O	O
.	O	O
We	O	O
report	O	O
here	O	O
the	O	O
complete	O	O
genomic	O	O
organization	O	O
of	O	O
the	O	O
human	O	O
CLD	B-disease	B-disease
gene	O	O
which	O	O
spans	O	O
approximately	O	O
39kb	O	O
,	O	O
and	O	O
comprises	O	O
21	O	O
exons	O	O
.	O	O
Our	O	O
results	O	O
demonstrate	O	O
that	O	O
in	O	O
certain	O	O
genetic	O	O
conditions	O	O
MLD	B-disease	B-disease
-	O	O
like	O	O
ARSA	O	B-disease
and	O	O
GS	O	B-disease
values	O	O
need	O	O
not	O	O
be	O	O
paralleled	O	O
by	O	O
clinical	O	O
disease	O	O
,	O	O
a	O	O
finding	O	O
with	O	O
serious	O	O
diagnostic	O	O
and	O	O
prognostic	O	O
implications	O	O
.	O	O
We	O	O
found	O	O
that	O	O
the	O	O
dominant	O	O
-	O	O
negative	O	O
effects	O	O
result	O	O
from	O	O
the	O	O
enhanced	O	O
DNA	O	O
binding	O	O
ability	O	O
of	O	O
these	O	O
mutants	O	O
.	O	O
1	O	O
%	O	O
of	O	O
American	O	O
Jews	O	O
,	O	O
28	O	O
%	O	O
of	O	O
their	O	O
familial	O	O
colorectal	B-disease	B-disease
cancer	I-disease	I-disease
cases	O	O
,	O	O
but	O	O
not	O	O
in	O	O
non	O	O
-	O	O
Jews	O	O
.	O	O
8	O	O
%	O	O
of	O	O
the	O	O
general	O	O
population	O	O
,	O	O
suggesting	O	O
that	O	O
it	O	O
is	O	O
not	O	O
disease	O	B-disease
associated	O	O
.	O	O
Segregation	O	O
distortion	O	O
in	O	O
myotonic	B-disease	B-disease
dystrophy	I-disease	I-disease
.	O	O
6	O	O
%	O	O
of	O	O
188	O	O
non	O	O
-	O	O
European	O	O
Jews	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
08	O	O
)	O	O
.	O	O
Our	O	O
previous	O	O
study	O	O
showed	O	O
that	O	O
this	O	O
Ashkenazi	O	B-disease
mutation	O	I-disease
also	O	O
occurs	O	O
in	O	O
Iraqi	O	O
Jews	O	O
with	O	O
a	O	O
similar	O	O
allelic	O	O
pattern	O	O
.	O	O
The	O	O
molecular	O	O
basis	O	O
of	O	O
C6	B-disease	B-disease
deficiency	I-disease	I-disease
in	O	O
the	O	O
western	O	O
Cape	O	O
,	O	O
South	O	O
Africa	O	O
.	O	O
I	O	O
.	O	O
Neuropsychological	O	O
analysis	O	O
assessed	O	O
verbal	O	O
and	O	O
visuospatial	O	O
intelligence	O	O
,	O	O
verbal	O	O
memory	O	O
,	O	O
and	O	O
reading	O	O
skills	O	O
.	O	O
However	O	O
,	O	O
some	O	O
of	O	O
these	O	O
patients	O	O
can	O	O
transmit	O	O
retinoblastoma	B-disease	B-disease
predisposition	O	O
to	O	O
their	O	O
offspring	O	O
.	O	O
These	O	O
assays	O	O
should	O	O
facilitate	O	O
screening	O	O
for	O	O
A	B-disease	B-disease
-	I-disease	I-disease
T	I-disease	I-disease
heterozygotes	O	I-disease
in	O	O
the	O	O
populations	O	O
studied	O	O
.	O	O
.	O	O
